Elemer Piros
Stock Analyst at Rodman & Renshaw
(3.06)
# 1,273
Out of 4,876 analysts
110
Total ratings
36.54%
Success rate
2.94%
Average return
Main Sectors:
Stocks Rated by Elemer Piros
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BTAI BioXcel Therapeutics | Initiates: Buy | $65 | $2.03 | +3,101.97% | 1 | Mar 19, 2025 | |
| FBLG FibroBiologics | Initiates: Buy | $12 | $0.71 | +1,585.39% | 1 | Dec 12, 2024 | |
| THAR Tharimmune | Initiates: Buy | $17 | $1.76 | +865.85% | 1 | Dec 6, 2024 | |
| QNCX Quince Therapeutics | Initiates: Buy | $11 | $1.50 | +633.33% | 1 | Oct 29, 2024 | |
| MNPR Monopar Therapeutics | Initiates: Buy | $50 | $35.01 | +42.82% | 6 | Oct 11, 2024 | |
| MIRA MIRA Pharmaceuticals | Initiates: Buy | $17 | $1.21 | +1,304.96% | 1 | Sep 30, 2024 | |
| ATHA Athira Pharma | Initiates: Buy | $22 | $0.30 | +7,160.73% | 1 | Aug 19, 2024 | |
| SAVA Cassava Sciences | Reiterates: Buy | $107 | $1.83 | +5,746.99% | 1 | Aug 8, 2024 | |
| CGTX Cognition Therapeutics | Reiterates: Buy | $14 | $0.32 | +4,214.33% | 1 | Jul 2, 2024 | |
| ANVS Annovis Bio | Reiterates: Buy | $67 | $2.17 | +2,987.56% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $2.30 | +1,769.57% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $5.89 | +205.60% | 7 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7.5 | $1.17 | +541.03% | 3 | Sep 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $2.25 | +566.67% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $21 | $6.74 | +211.57% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $2.66 | +1,328.57% | 9 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $0.73 | +5,349.59% | 2 | Jul 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $5.94 | +741.75% | 5 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $114 | $8.58 | +1,228.67% | 3 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $200 | $3.92 | +5,002.04% | 6 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $3.41 | +574.49% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $33 | $12.40 | +166.13% | 3 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $40 | $18.40 | +117.39% | 7 | Apr 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $40 | $0.79 | +4,995.54% | 3 | Jan 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $1.67 | +2,115.57% | 1 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $32 | $3.81 | +739.90% | 2 | Jun 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $77 | $14.41 | +434.35% | 2 | Dec 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $0.62 | +11,164.89% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.02 | - | 5 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $50 | $16.07 | +211.14% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $33 | $3.87 | +752.71% | 2 | Oct 22, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $9.94 | - | 3 | Jul 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $3.32 | +683.13% | 3 | May 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $142.69 | -80.38% | 1 | Sep 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $525 → $850 | $5.90 | +14,306.78% | 1 | Oct 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $21 | $9.46 | +121.99% | 2 | Jul 12, 2017 |
BioXcel Therapeutics
Mar 19, 2025
Initiates: Buy
Price Target: $65
Current: $2.03
Upside: +3,101.97%
FibroBiologics
Dec 12, 2024
Initiates: Buy
Price Target: $12
Current: $0.71
Upside: +1,585.39%
Tharimmune
Dec 6, 2024
Initiates: Buy
Price Target: $17
Current: $1.76
Upside: +865.85%
Quince Therapeutics
Oct 29, 2024
Initiates: Buy
Price Target: $11
Current: $1.50
Upside: +633.33%
Monopar Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $50
Current: $35.01
Upside: +42.82%
MIRA Pharmaceuticals
Sep 30, 2024
Initiates: Buy
Price Target: $17
Current: $1.21
Upside: +1,304.96%
Athira Pharma
Aug 19, 2024
Initiates: Buy
Price Target: $22
Current: $0.30
Upside: +7,160.73%
Cassava Sciences
Aug 8, 2024
Reiterates: Buy
Price Target: $107
Current: $1.83
Upside: +5,746.99%
Cognition Therapeutics
Jul 2, 2024
Reiterates: Buy
Price Target: $14
Current: $0.32
Upside: +4,214.33%
Annovis Bio
Jul 2, 2024
Reiterates: Buy
Price Target: $67
Current: $2.17
Upside: +2,987.56%
Jun 21, 2024
Initiates: Buy
Price Target: $43
Current: $2.30
Upside: +1,769.57%
Jun 13, 2024
Initiates: Buy
Price Target: $18
Current: $5.89
Upside: +205.60%
Sep 14, 2023
Maintains: Buy
Price Target: $12 → $7.5
Current: $1.17
Upside: +541.03%
Aug 9, 2023
Reiterates: Buy
Price Target: $15
Current: $2.25
Upside: +566.67%
Aug 4, 2023
Reiterates: Buy
Price Target: $21
Current: $6.74
Upside: +211.57%
Aug 3, 2023
Reiterates: Buy
Price Target: $38
Current: $2.66
Upside: +1,328.57%
Jul 10, 2023
Reiterates: Buy
Price Target: $40
Current: $0.73
Upside: +5,349.59%
Jun 30, 2023
Reiterates: Buy
Price Target: $50
Current: $5.94
Upside: +741.75%
Jun 20, 2023
Reiterates: Buy
Price Target: $114
Current: $8.58
Upside: +1,228.67%
Jun 20, 2023
Maintains: Buy
Price Target: $260 → $200
Current: $3.92
Upside: +5,002.04%
May 16, 2023
Reiterates: Buy
Price Target: $23
Current: $3.41
Upside: +574.49%
Mar 2, 2023
Reiterates: Buy
Price Target: $33
Current: $12.40
Upside: +166.13%
Apr 14, 2022
Downgrades: Sell
Price Target: $40
Current: $18.40
Upside: +117.39%
Jan 4, 2022
Upgrades: Buy
Price Target: $40
Current: $0.79
Upside: +4,995.54%
Dec 1, 2021
Initiates: Buy
Price Target: $37
Current: $1.67
Upside: +2,115.57%
Jun 30, 2021
Maintains: Buy
Price Target: $38 → $32
Current: $3.81
Upside: +739.90%
Dec 23, 2020
Downgrades: Sell
Price Target: $77
Current: $14.41
Upside: +434.35%
Oct 12, 2020
Initiates: Buy
Price Target: $70
Current: $0.62
Upside: +11,164.89%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $8.02
Upside: -
Nov 19, 2019
Maintains: Neutral
Price Target: $24 → $50
Current: $16.07
Upside: +211.14%
Oct 22, 2019
Assumes: Overweight
Price Target: $33
Current: $3.87
Upside: +752.71%
Jul 11, 2019
Upgrades: Overweight
Price Target: n/a
Current: $9.94
Upside: -
May 6, 2019
Initiates: Overweight
Price Target: $26
Current: $3.32
Upside: +683.13%
Sep 11, 2018
Initiates: Overweight
Price Target: $28
Current: $142.69
Upside: -80.38%
Oct 12, 2017
Maintains: Overweight
Price Target: $525 → $850
Current: $5.90
Upside: +14,306.78%
Jul 12, 2017
Maintains: Overweight
Price Target: $35 → $21
Current: $9.46
Upside: +121.99%